Lineage Cell TherapeuticsvsUnitedHealth

LCTX and UNH stock compared: price, dividend, valuation and results, from SEC filings.

LCTX

Lineage Cell Therapeutics, Inc.

$0.77

Value $192M

-6.10%
LCTX's page

UNH

UnitedHealth Group Incorporated

$339.85

Value $308B

+2.84%
UNH's page

Lineage Cell Therapeutics (LCTX) has a market value of $192M and UnitedHealth (UNH) $308B. Over the last year, with dividends, LCTX moved -55.0% and UNH +12.9%. Dividend yield: LCTX none, UNH 2.67%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    LCTX$192M

    UNH$308B

    UNH is 1,604 times LCTX

  • Revenue, 12 months

    LCTX$11M

    UNH$450B

    UNH is 41,497 times LCTX

  • Net income, 12 months

    LCTX$1.8M

    UNH$15.9B

    UNH is 9,061 times LCTX

  • Operating margin

    LCTX-280.3%

    UNH5.3%

    285.6 points apart

  • ROIC

    LCTX-48.3%

    UNH11.3%

    59.6 points apart

  • P/E

    LCTX–

    UNH19.4

  • Dividend yield

    LCTX0.0%

    UNH2.7%

    2.7 points apart

  • 5-year return

    LCTX-66.4%

    UNH-15.4%

    51.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

LCTX-66.4%

UNH-15.4%

5010015020222023202420252026
Returns by period
PeriodLCTXWith dividendsUNHWith dividends
1 year since November 19, 2025-55.0%Price -55.0%+12.9%Price +10.0%
3 years since November 20, 2023-28.0%-10.4% a yearPrice -28.0%-32.4%-12.2% a yearPrice -36.5%
5 years since November 19, 2021-66.4%-19.6% a yearPrice -66.4%-15.4%-3.3% a yearPrice -22.8%
10 years since November 22, 2016-76.2%-13.4% a yearPrice -76.2%+163.6%+10.2% a yearPrice +123.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

LCTXLineage Cell TherapeuticsUNHUnitedHealth

Valuation

LCTXUNH
Valuation
Price$0.77$339.85
Market value$192M$308B
Enterprise value (EV)$147M$354B
P/E–19.4
P/E, 5-year median–25.0
P/B2.93.0
EV/EBIT–14.8
Free cash flow yield–7.4%

Results and growth

LCTXUNH
Results and growth
Revenue, 12 months$11M$450B
Net income, 12 months$1.8M$15.9B
Free cash flow, 12 months-$26M$22.8B
Earnings per share, 12 months-$0.09$17.52
Revenue growth, year on year53.2%11.8%
Revenue growth a year, past+51.5%over 5 years+11.7%over 5 years
EPS growth a year, past–-3.8%over 5 years

Margins and returns on capital

LCTXUNH
Margins and returns on capital
Gross margin–88.3%
Operating margin-280.3%5.3%
Net margin16.2%3.5%
ROIC-48.3%11.3%
ROE3.5%15.5%

Balance sheet

LCTXUNH
Balance sheet
Cash$45M$28.5B
Total debt$2.0M$74.3B
Net debt / EBITDA–1.6
Interest cover–6.2×

Dividends and buybacks

LCTXUNH
Dividends and buybacks
Dividend yield–2.7%
Dividend per share, 12 months–$9.06
Dividend growth a year, past–+12.6%over 5 years
Buyback yield–1.8%
Shareholder yield–4.5%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: LCTX or UNH

Didn't find what you were looking for?

Ask us
Which is bigger, Lineage Cell Therapeutics or UnitedHealth?

By market value, UnitedHealth ($308B) is about 1,604.4 times Lineage Cell Therapeutics ($192M), at today's prices.

How did LCTX and UNH stock do over the last 10 years?

Since November 22, 2016, LCTX's price moved -76.2% and UNH's +123.2%. With dividends: LCTX -76.2% (-13.4% a year), UNH +163.6% (+10.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, LCTX or UNH?

The dividend yield at today's price is none for Lineage Cell Therapeutics and 2.67% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.

Which has the higher profit margins, Lineage Cell Therapeutics or UnitedHealth?

Over the last twelve months, the net margin was 16.2% for Lineage Cell Therapeutics and 3.5% for UnitedHealth, and the operating margin -280.3% and 5.3%. Revenue was $11M and $450B.

Which is the better investment, Lineage Cell Therapeutics or UnitedHealth?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.